Loading
Today's engineered T-cell therapies for sarcoma only work in the ~40-50% of people with one particular HLA type; new receptors for other HLA types would open them to everyone.
Afamitresgene autoleucel and letetresgene autoleucel, the engineered T-cell receptor therapies for synovial sarcoma, work only in people whose HLA type is A*02:01, A*02:05 or A*02:06, which excludes around half of patients. This idea would open TCR-T to everyone by discovering receptors that recognise the same antigens, MAGE-A4 and NY-ESO-1, presented by other alleles such as HLA-A*24, HLA-B*35 and HLA-C*07. The rationale is that antigen expression is independent of HLA type, so the barrier is a receptor discovery problem, and platforms at Immatics, T-knife and Adaptimmune have already isolated candidate receptors. The proposed test is a basket phase 1/2 across HLA types; the evidence is preclinical, and the idea addresses the bottleneck of rare and paediatric cancers without markets.
Shares MAGE-A4, Afamitresgene autoleucel, SPEARHEAD-1: afamitresgene autoleucel, the first engineered T-cell receptor therapy approved for a solid tumour, in synovial sarcoma, TCR-T cell therapy.
Shares Letetresgene autoleucel, Afamitresgene autoleucel, Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).
Shares Afamitresgene autoleucel, SPEARHEAD-1: afamitresgene autoleucel, the first engineered T-cell receptor therapy approved for a solid tumour, in synovial sarcoma, Sarcomas (soft tissue, bone, GIST).
Shares Letetresgene autoleucel, TCR-T cell therapy, Sarcomas (soft tissue, bone, GIST).
Shares Afamitresgene autoleucel, TCR-T cell therapy, Sarcomas (soft tissue, bone, GIST).
Shares MAGE-A4, TCR-T cell therapy.
Shares Letetresgene autoleucel, MAGE-A4, Afamitresgene autoleucel, TCR-T cell therapy.